David Dolphin Email & Phone Number

David Dolphin, was the founding CEO of the British Columbia Innovation Council. As the Vice-President Technology Development at Quadra Logic Technologies he was instrumental for the discovery, development and commercialization of Visudyne, and the establishment of one of Canada’s most renowned university spin-off companies, QLT Inc.. Visudyne has already saved the vision of hundreds of thousands of people afflicted with “wet” age-related macular degeneration. Visudyne is the most successful ophthalmic product ever registered., it has been approved in more than 70 countries; more than 1,000,000 patients have been treated and more than $5,000,000,000 of the drug has been sold. Dolphin holds more than 260 patents and is the author and editor of nineteen books and has published over 400 research papers. In 2002 David (along with Julia Levy) was awarded the Prix GalienIn 2004 he was designated a Hero of Chemistry, the highest award the American Chemical Society gives to an industrial chemist. Before joining QLT he was the Acting Dean of Science at UBC and he has been acting V.P. Research at UBC in 1999-2000 and in 2005. He is a Fellow of the Royal Society of Canada and received the Friesen Rygiel Prize in 2002 and the same year he was elected a Fellow of the Royal Society (London). In 2005 he was awarded the NSERC Herzberg Gold Medal, the Council's highest honour. In the spring of 2006 David was appointed an Officer of the Order of Canada. In addition to his administrative experience at QLT and UBC David has sat on many boards including those of The Canadian Foundation for Innovation (Chair of the Governance Committee), Genome BC (Past Chair), PrioNet (Chair), Alberta Innovates-Health Solutions, TRIUMF, the Michael Smith Foundation for Health Research, The Chemical Institute of Canada (Past Chair) and he was a founding board member of Neuromed Inc.He was also a founding member and is the current Chair of the Center for Drug Research and Development.

Listed skills include Lifesciences, Research, Biotechnology, R&D, and 35 others.